Published in 2012 – Ann Oncol 2012; 23 (Suppl 7): vii86-vii91.
Authors: R. Dummer, A. Hauschild, M. Guggenheim, U. Keilholz, G. Pentheroudakis
ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of cutaneous melanoma focus on featured changes in the treatment of systemic metastatic disease. Tumour tissues preferentially of metastatic lesions should be screened for mutations (BRAF, NRAS, c-Kit, GNA11, GNAQ) which help to direct patients to the appropriate clinical trials and in the long term to validate their prognostic relevance. Ipilimumab and in the presence of BRAF V600 mutation, vemurafenib, are optimal choices for first-line therapy of patients with metastatic melanoma.